5F-Cumyl-PINACA, also known as 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, is a synthetic cannabinoid. It is part of a class of compounds designed to mimic the effects of delta-9-tetrahydrocannabinol (THC), the active component in cannabis. This compound has gained attention due to its potent agonistic activity at cannabinoid receptors, particularly CB1 and CB2 receptors .

Please be aware that all articles and product information presented on BenchChem are intended solely for informational purposes. The products available for purchase on BenchChem are specifically designed for in-vitro studies, which are conducted outside of living organisms. In-vitro studies, derived from the Latin term “in glass,” involve experiments performed in controlled laboratory settings using cells or tissues. It is important to note that these products are not categorized as medicines or drugs, and they have not received approval from the FDA for the prevention, treatment, or cure of any medical condition, ailment, or disease. We must emphasize that any form of bodily introduction of these products into humans or animals is strictly prohibited by law. It is essential to adhere to these guidelines to ensure compliance with legal and ethical standards in research and experimentation.

Synthetic CUMYL-PINACA powder cannabinoids

are the largest and most structurally diverse class of new psychoactive substances, with manufacturers often using isomerism to evade detection and circumvent legal restriction. The regioisomeric methoxy? and fluorine?substituted analogs of SDB?006 (N?benzyl?1?pentyl?1H?indole?3?carboxamide) were synthesized and could not be differentiated by gas chromatography–mass spectrometry (GC–MS), but were distinguishable by liquid chromatography–quadrupole time?of?flight–MS (LC–QTOF–MS). In a fluorescence?based plate reader membrane potential assay, SDB?006 acted as a potent agonist at human cannabinoid receptors (CB1 EC50 = 19 nM). All methoxy? and fluorine?substituted analogs showed reduced potency compared to SDB?006, although the 2?fluorinated analog (EC50 = 166 nM) was comparable to known synthetic cannabinoid RCS?4 (EC50 = 146 nM). Using biotelemetry in rats, SDB?006 and RCS?4 evoked comparable reduction in body temperature (~0.7°C at a dose of 10 mg/kg), suggesting lower potency than the recent synthetic cannabinoid AB?CHMINACA (>2°C, 3 mg/kg).